Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs

References

• Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the USA, 1999 through 2002. Ann Intern Med. 2006;144:1–7.
   Web of Science ®Google Scholar
• Felmlee DJ, Hafirassou ML, Lefevre M, et al. Hepatitis C virus, cholesterol and lipoproteins–impact for the viral life cycle and pathogenesis of liver disease. Viruses. 2013;5:1292–1324.
   PubMed Web of Science ®Google Scholar
• Chew KW, Bhattacharya D, McGinnis KA, et al. Short communication: coronary heart disease risk by framingham risk score in hepatitis C and HIV/hepatitis C-coinfected persons. AIDS Res Hum Retroviruses. 2015;31:718–722.
   Web of Science ®Google Scholar
• Imazeki F, Yokosuka O, Fukai K, et al. Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients. Liver Int. 2008;28:355–362.
   PubMed Web of Science ®Google Scholar
• Svegliati-Baroni G, Ridolfi F, Di Sario A, et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology. 1999;29:1743–1751.
   PubMed Web of Science ®Google Scholar
• Petit JM, Bour JB, Galland-Jos C, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol. 2001;35:279–283.
   PubMed Web of Science ®Google Scholar
• Wang CS, Yao WJ, Chang TT, et al. The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses. Cancer Epidemiol Biomarkers Prev. 2009;18:2054–2060.
   Web of Science ®Google Scholar
• Khattab M, Eslam M, Sharwae MA, et al. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol. 2010;105:1970–1977.
   PubMed Web of Science ®Google Scholar
• Grasso A, Malfatti F, Testa R. Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C? World J Gastroenterol. 2013;19:6947–6956.
   PubMed Web of Science ®Google Scholar
• Wantuck JM, Ahmed A, Nguyen MH. Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther. 2014;39:137–147.
   PubMed Web of Science ®Google Scholar
• El Kassas M, Elbaz T, Hafez E, et al. Safety of direct antiviral agents in the management of hepatitis C. Expert Opin Drug Saf. 2016;15:1643–1652.
   PubMed Web of Science ®Google Scholar
• Meissner EG, Lee YJ, Osinusi A, et al. Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology. 2015;61:790–801.
   PubMed Web of Science ®Google Scholar
• Townsend K, Meissner EG, Sidharthan S, et al. Interferon-free treatment of hepatitis C virus in HIV/hepatitis C virus-coinfected subjects results in increased serum low-density lipoprotein concentration. AIDS Res Hum Retroviruses. 2015;32:456–462.
   Web of Science ®Google Scholar
• Gitto S, Cicero AFG, Loggi E, et al. Worsening of serum lipid profile after direct acting antiviral treatment. J Hepatol. 2017;66:S740.
   Web of Science ®Google Scholar
• Buti M, Calleja JL, Lens S, et al. Simeprevir in combination with sofosbuvir in treatment-naive and experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO). Aliment Pharmacol Ther. 2016;45:468–475.
   Web of Science ®Google Scholar
• Mauss S, Berger F, Wehmeyer MH, et al. Effect of antiviral therapy for HCV on lipid levels. Antivir Ther. 2016;21:81–88.
   Google Scholar
• Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A. 2005;102:2561–2566.
   PubMed Web of Science ®Google Scholar
• Hashimoto S, Yatsuhashi H, Abiru S, et al. Rapid increase in serum low-density lipoprotein cholesterol concentration during hepatitis C interferon-free. Treatment PLoS One. 2016;11:e0163644.
   PubMed Web of Science ®Google Scholar
• Endo D, Satoh K, Shimada N, et al. Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b. World J Gastroenterol. 2017;23:2355–2364.
   Web of Science ®Google Scholar
• Khattab MA, Eslam M, Aly MM, et al. Serum lipids and chronic hepatitis C genotype 4: interaction and significance. Ann Hepatol. 2011;11:37–46.
   Web of Science ®Google Scholar
• El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004;126:460–468.
   PubMed Web of Science ®Google Scholar
• Hsu CS, Liu CJ, Liu CH, et al. High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C. Liver Int. 2008;28:271–277.
   PubMed Web of Science ®Google Scholar
• Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 2008;134:416–423.
   PubMed Web of Science ®Google Scholar
• Serfaty L, Forns X, Goeser T, et al. Insulin resistance and response to telaprevir plus peginterferon alpha and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut. 2012;61:1473–1480.
   PubMed Web of Science ®Google Scholar
• Fattovich G, Covolo L, Pasino M, et al. The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. Liver Int. 2011;31:66–74.
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Patel K, Chuang WL, et al. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut. 2009;61:128–134.
   Google Scholar
• Delgado-Borrego A, Jordan SH, Negre B, et al. Reduction of insulin resistance with effective clearance of hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol. 2010;8:458–462.
   PubMed Web of Science ®Google Scholar
• Arase Y, Suzuki F, Suzuki Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology. 2009;49:739–744.
   PubMed Web of Science ®Google Scholar
• Aghemo A, Prati GM, Rumi MG, et al. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. Hepatology. 2012;56:1681–1687.
   PubMed Web of Science ®Google Scholar